Amarin Corp Ads (AMRN) 2.19 $AMRN Amarin Appoints

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 8:07 PM

Amarin Corp Ads (AMRN) 2.19 $AMRN

Amarin Appoints Michael W. Kalb Chief Financial Officer
Marketwire Canada - Thu Jun 30, 6:30AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - June 30, 2016) - Amarin Corporation plc (NASDAQ: AMRN) announced that starting today Michael W. Kalb has joined its senior management team as senior vice president and chief financial officer. A seasoned financial executive, Mr. Kalb brings over 20 years of international financial operations and accounting advisory experience.
AMRN: 2.19 (unch)

Featured Research Report on Drug Manufacturers Stocks
ACCESSWIRE - Tue Jun 14, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 14, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers-Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
UTHR: 110.24 (-0.92), AMRN: 2.19 (unch), DEPO: 19.03 (+0.26), IONS: 25.28 (-0.08)

Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Patients With Type 2 Diabetes and Persistent High Triglycerides
Marketwired - Sat Jun 11, 10:00AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - June 11, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced additional data on Vascepa (icosapent ethyl) presented at the annual meeting of the American Diabetes Association (ADA) supporting its efficacy in reducing concentrations of potentially atherogenic lipoproteins (lipoproteins that could promote fat deposits in arteries) in patients with Type 2 diabetes and persistent high triglyceride (TG) levels despite statin therapy.
AMRN: 2.19 (unch)

Vascepa(R) (Icosapent Ethyl) Data to Be Presented at American Diabetes Association's 76th Scientific Sessions
Marketwire Canada - Mon Jun 06, 6:30AM CDT
BEDMINSTER, NJ AND DUBLIN, IRELAND--(Marketwired - June 06, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced that new data related to Vascepa® (icosapent ethyl) will be presented at the upcoming American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans (June 10-14) and published as an abstract in the Diabetes® Abstract Book.
AMRN: 2.19 (unch)

Amarin (AMRN) Looks Good: Stock Adds 6.7% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:40AM CDT
Amarin Corporation plc (AMRN) saw its shares rise almost 7% in the last trading session.
ANIP: 55.38 (-1.13), AMRN: 2.19 (unch)

Amarin to Present at the Jefferies 2016 Global Healthcare Conference
Marketwire Canada - Wed Jun 01, 7:01AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - June 01, 2016) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the Jefferies 2016 Global Healthcare Conference in New York City on Tuesday, June 7, 2016, at 8:00 a.m. ET.
AMRN: 2.19 (unch)

Amarin Announces FDA New Chemical Entity Market Exclusivity Determination for Vascepa(R) (icosapent ethyl) Capsules
Marketwire Canada - Tue May 31, 12:30PM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - May 31, 2016) - Amarin Corporation plc (NASDAQ: AMRN) announced today that the U.S. Food and Drug Administration (FDA) has determined that Vascepa® (icosapent ethyl) capsules are eligible for five-year, new chemical entity (NCE), marketing exclusivity pursuant to the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. This determination provides Vascepa with the benefits of NCE exclusivity afforded by statute. NCE exclusivity for Vascepa runs from its date of FDA approval on July 26, 2012 and extends until July 26, 2017. The statutory 30-month stay triggered by patent litigation following generic application submissions permitted on July 26, 2016 would expire on January 26, 2020, seven-and-a-half years from FDA approval.
AMRN: 2.19 (unch)

Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Key Lipid Parameters in Subgroup of Women With Very High Triglyceride Levels
Marketwired - Fri May 20, 9:50AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - May 20, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced the presentation of a poster at the annual meeting of the National Lipid Association (NLA) further characterizing the efficacy and safety of Vascepa® (icosapent ethyl) in women with very high triglyceride levels.
AMRN: 2.19 (unch)

Vascepa(R) (icosapent ethyl) and Eicosapentaenoic Acid (EPA) Data to Be Presented at National Lipid Association 2016 Scientific Sessions
Marketwire Canada - Wed May 11, 6:30AM CDT
BEDMINSTER, NJ AND DUBLIN, IRELAND--(Marketwired - May 11, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced that new data related to Vascepa® (icosapent ethyl) and eicosapentaenoic acid (EPA) will be presented at the upcoming National Lipid Association 2016 Scientific Sessions in New Orleans (May 19-22).
AMRN: 2.19 (unch)

Amarin Reports First Quarter 2016 Financial Results and Provides Update on Operations
Marketwire Canada - Thu May 05, 6:00AM CDT
Product Revenue up 63% Over Prior Year; REDUCE-IT Cardiovascular Outcomes Study Achieves Target Enrollment; Preparation for Interim Analysis by Independent Data Monitoring Committee Underway; Management to Host Conference Call at 8:00 a.m. ET Today
AMRN: 2.19 (unch)

Investor Calendar Invites You to the Amarin First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 5, 2016
ACCESSWIRE - Wed May 04, 3:05PM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / May 4, 2016 / Amarin Corporation plc (NASDAQ: AMRN) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Thursday, May 5, 2016 at 8:00 AM Eastern Time.
AMRN: 2.19 (unch)

Amarin to Report First Quarter 2016 Results and Host Conference Call on May 5, 2016
Marketwired - Thu Apr 28, 6:44AM CDT
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2016 financial results and provide an operational update on Thursday, May 5, at 8:00 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.
AMRN: 2.19 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ICAC's Landmark Program Strengthens Africa's Anti-Corruption Efforts

A Bold Step Towards Integrity Corruption has long been a thorn in the side of progress for many regions, and watching the Hong Kong International Academy Against Corruption (HKIAAC) step up to the plate in Africa feels like a much-needed move. I mean, when you've got the collective wisdom of folks who've been through the wringer on these issues, you'd be wise to pay heed....

Hyliion Faces Legal Whirlwind After Stock Tumbles 19.3%

Battered by Allegations: Hyliion in Legal Crosshairs Here's a hot mess Hyliion's found itself in. Amidst allegations of deception, the stock has dropped a hefty 19.3%. For anyone keeping tabs on this one, the legal eagles over at The Law Offices of Frank R. Cruz have swooped in, announcing a class action that's got all the trimmings of your classic securities mess. The...

Ardelyx Investors Face Lawsuit Over Misleading Claims

Investors Land in Hot Water with Ardelyx Alright, folks, here we go again. New York's courtroom dramas are in full swing with Ardelyx, Inc. at center stage, and not in a good way. The DJS Law Group has rallied the troops, reminding investors caught in the storm of a class action lawsuit. Specifically, it's all about alleged violations of the Securities Exchange Act of...

Suunto Unleashes High-Tech Race 3S Watch with AI Coach

The Latest in Performance Gear: Suunto's Race 3S Nobody wants their gear to be a limitation, especially out in the wild where every step counts. Enter Suunto's Race 3S—a watch that looks to change the game for those passionate about trail running. This gadget's packed with features meant for athletes who are serious about their tech, yet light enough to make you forget...

Anita Eno: 2027's Top Trailblazing Businesswoman

Anita Eno's Well-Deserved Recognition You've got to respect a story where someone claws their way up from humble beginnings to a position of serious influence. Anita Eno, Founder and CEO of Prayers Are Answered Inc., is one of those impressive figures, recently bagging the 2027 American Business Woman of the Year title. This accolade, dished out by the American Business...

Minesto Joins Sweden-Indonesia Partnership in Energy Shift

Minesto's Big Splash in Indonesia's Energy Transition Here we go, folks. Minesto's taking the plunge into Indonesia's uncharted tidal waters under a Sweden-backed partnership. This Swedish underdog in ocean energy is ready to shake things up and ride the Indonesian currents, thanks to the Sweden-Indonesia Sustainability Partnership. Now, why should this matter to you, the...

NVIDIA GTC Unveils Fleet's New AI Device Support

Expanding the AI Frontier: Fleet Meets NVIDIA NVIDIA just pulled a major move at their GTC Berlin event, rolling out a comprehensive suite of device management for their AI hardware ecosystem through Fleet. Picture this: IT folks can now handle NVIDIA’s flagship AI gear alongside all those pesky other devices without losing their minds or sleep. From RTX PRO...

PuroClean Shines in Franchise Rankings with Global Growth

Diversifying with Property Restoration Stroll through any franchise expo and the buzzwords are all there: growth, opportunity, scalability. But in the crowded room of glittery pitches, the ones really shaking things up are those that go beyond the razzle-dazzle—brands like PuroClean that stick it to the competition with real, boots-on-the-ground expansion. The...

Plaid Eyes Data Horizons; Acorns Embraces Gen Z

Fintech's Next Frontier: Plaid's Vision You ever get the feeling some folks see further down the road than others? That's Plaid CTO Will Robinson, chatting up the NYSE folks at Money20/20. The man’s got his eyes on what he calls "making sense" of financial data—no small feat in our swamped digital world. Plaid ain't some penny stock operation, either. This is an $8...

Hengrui Pharma at ESMO 2026: Innovations in Oncology

Pushing Boundaries at ESMO 2026 If there's one place where the future of cancer treatment is being etched out, it's at forums like the ESMO Congress. This year, Hengrui Pharma is rolling in with 64 research findings hotter than a two-dollar pistol, all set to make waves in oncology. From breast to lung cancer, they're covering the lot and showcasing a blend of established...